Linares-Gonzalez L, Lozano-Lozano I, Gutierrez-Rojas L, et al. - In a cohort of patients with moderate-to-severe atopic dermatitis (AD), 79% of patients had sexual dysfunction (SD). Dupilumab exerts a positive impact on the levels of SD in moderate-to-severe AD patients, including both male and female populations.

• This cross-sectional study involved 31 patients, 18 men and 13 women, who were suffering from moderate-to-severe AD.

• SD was present in 66.9% of males and 76.9% (n = 10) of females sampled.

• Six months post-initiation of dupilumab treatment, no treatment discontinuation occurred due to efficacy or safety issues.

• Relative to baseline, all severity indices (SCORAD, EASI, VAS pruritus, and DLQI) showed significant improvement by more than 50%.

• Both male and female patients had a sexual dysfunction index improved by four points.

• In many large population studies on SD in moderate-to-severe atopic AD patients, the focus is on only male gender and clinical diagnoses, instead of specific and validated questionnaires.